Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 14/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26674032 | 0.87 | SMO (0.61) | SMOMAPTGRM5MEN1ALDH1A1 | |
| SCHEMBL26674008 | 0.85 | MAPT (0.73) | SMOMAPTGRM5XBP1NPSR1 | |
| SCHEMBL26673885 | 0.85 | SMO (0.63) | SMOMAPTGRM5 | |
| SCHEMBL26673915 | 0.85 | GRM5 (0.61) | SMOMAPTGRM5MEN1ALDH1A1 | |
| SCHEMBL26673897 | 0.83 | POLB (0.60) | SMOMAPTGRM5 | |
| SCHEMBL26674074 | 0.82 | GRM5 (0.55) | SMOMAPTGRM5MEN1ALDH1A1 | |
| SCHEMBL26673793 | 0.82 | GRM5 (0.55) | SMOMAPTGRM5MEN1ALDH1A1 | |
| SCHEMBL13860720 | 0.82 | MAPT (0.57) | MAPTMEN1ALDH1A1KMT2AXBP1 | |
| SCHEMBL30640579 | 0.82 | MAPT (0.54) | MAPTGRM5ALDH1A1CYP1A2XBP1 | |
| SCHEMBL30640574 | 0.82 | GRM5 (0.53) | SMOMAPTGRM5MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| EP-4526291-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | The Board of Regents of the University of Texas System (US) | 2025-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | DDIT3, ATF4, EIF2AK3 | SMO 3520/4885MAPT 3664/4885GRM5 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.